Aduhelm Approval Brings Potential for an Evolving Alzheimer’s Disease Treatment Market and Challenges for Healthcare Costs

On June 7th, the FDA granted accelerated approval for Biogen’s amyloid beta-directed anti-body Aduhelm (aducanumab), the first potentially disease-modifying treatment and first approval for Alzheimer’s disease (AD) in nearly two decades.